Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Clinical Oncology

• Publication date

  2001-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2001.19.7.1901PMID 11283121
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemotherapy with carboplatin/docetaxel for primary and recurrent epithelial ovarian cancer

  2001cited by this paper
• Neurotoxicity associated with a regimen of carboplatin (AUC 5–6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies

  2001cited by this paper
• Second-line treatment of ovarian cancer.

  2000cited by this paper
• Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.

  2000cited by this paper
• Experience with prophylactic oral ciprofloxacin in gynecological cancer patients developing severe chemotherapy-induced neutropenia

  2000cited by this paper
• Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

  2000cited by this paper
• Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group.

  1999cited by this paper
• Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group.

  1998cited by this paper
• Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.

  1998cited by this paper
• How many more nails to seal the coffin of dose intensity?

  1997cited by this paper
• Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study.

  1997cited by this paper
• A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: a comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals.

  1996cited by this paper
• Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

  1996cited by this paper
• Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity.

  1996cited by this paper
• Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.

  1995cited by this paper
• Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center.

  1995cited by this paper
• Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer.

  1995cited by this paper
• Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.

  1994cited by this paper
• The impact of received dose intensity on the outcome of advanced ovarian cancer.

  1993cited by this paper

• Incarcerated femoral hernia containing the ipsilateral fallopian tube without ovarian involvement: A rare case report

  2025cites this paper
• Clarifying Blood Indices in Patients With Ovarian Cancer

  2025cites this paper
• Microtubule-Targeting Agents: Disruption of the Cellular Cytoskeleton as a Backbone of Ovarian Cancer Therapy.

  2024cites this paper
• Comparative Survival Outcomes of Hyperthermic Intraperitoneal Chemotherapy, Intraperitoneal Chemotherapy and Intravenous Chemotherapy for Primary Advanced Ovarian Cancer: A Network Meta-Analysis

  2023cites this paper
• (NDLS) based chemotherapy in patients with metastatic epithelial ovarian carcinoma. In the present multicenter study, the medical records of patients who received NDLS

  2021cites this paper
• Efficacy and safety of nanosomal docetaxel lipid suspension based chemotherapy in metastatic ovarian carcinoma: A retrospective study.

  2021cites this paper
• Assessment of Depression and Anxiety in Breast Cancer Patients Undergoing Radiotherapy in Palestine

  2020cites this paper
• Maligne Tumoren der Tube

  2018cites this paper
• Cancer chemotherapeutics in rheumatoid arthritis: A convoluted connection.

  2018cites this paper
• Pentacyclic triterpenoids: Discovery of new drugs with antitumour activity

  2017cites this paper
• Design, synthesis and biological evaluation of novel C-29 carbamate celastrol derivatives as potent and selective cytotoxic compounds.

  2017cites this paper
• High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer—A Phase 2 Cohort Study

  2016cites this paper
• Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review

  2015cites this paper
• Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic Chemotherapy

  2015cites this paper
• Taxanes in combination with biologic agents for ovarian and breast cancers

  2014cites this paper
• Taxanes: their impact on gynecologic malignancy

  2014cites this paper
• Allergic and Pseudoallergic Drug Reactions

  2014cites this paper
• A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer

  2014cites this paper
• Holding back sharing concerns, dispositional emotional expressivity, perceived unsupportive responses and distress among women newly diagnosed with gynecological cancers.

  2014cites this paper
• Chemotherapy hypersensitivity reactions in ovarian cancer.

  2014cites this paper
• Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: illustration with the case of taxane therapeutics.

  2014cites this paper
• Docetaxel Obs Cancer BPL 01 2012

  2012cites this paper
• Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer.

  2012cites this paper
• Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study

  2012cites this paper
• A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum‐sensitive ovarian cancer

  2012influential citation
• Elderly and very elderly advanced ovarian cancer patients: does the age influence the surgical management?

  2012cites this paper
• Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer.

  2011cites this paper
• Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).

  2011cites this paper
• Evaluation of the Patient-Generated Subjective Global Assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: a pilot study.

  2011cites this paper
• Randomized phase II study comparing docetaxel plus cisplatin , docetaxel plus carboplatin , and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma : a Japanese Gynecologic Oncology Group study ( JGOG 2041 )

  2011cites this paper
• Artyku ł y przegl ą dowe • Review articles

  2011cites this paper
• Docetaxel and Carboplatin (DC) for Ovarian Cancer

  2010cites this paper
• Incarcerated Femoral Hernia Containing Ipsilateral Fallopian Tube

  2010cites this paper
• Tumeurs de la trompe de Fallope

  2010cites this paper
• Positive experience of Intraperitoneal Chemotherapy followed by Intravenous Chemotherapy in Heavily Pretreated Patients with Suboptimal Residual Ovarian Cancer and Primary Peritoneal Cancer

  2010influential citation
• Microarray Analysis of Early Stage Serous Ovarian Cancers Shows Profiles Predictive of Favorable Outcome

  2009cites this paper
• Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance

  2009cites this paper
• Melding a New 3-Dimensional Agarose Colony Assay with the Emax Model to Determine the Effects of Drug Combinations on Cancer Cells

  2009cites this paper
• Taxanes in the management of gynecologic malignancies

  2008cites this paper
• Long-Term Trajectories of Psychological Adaptation Among Women Diagnosed With Gynecological Cancers

  2008cites this paper
• Ovarian Tumor Targeting of Docetaxel-Loaded Liposomes Mediated by Luteinizing Hormone-Releasing Hormone Analogues

  2008cites this paper
• LHRHa aided liposomes targeting to human ovarian tumor cells: preparation and cellular uptake.

  2008cites this paper
• Evaluation of the Combination of Docetaxel/Carboplatin in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN): A Southwest Oncology Group Phase II Study

  2007cites this paper
• Primary fallopian tube carcinoma in a 51-year-old postmenopausal woman--case report.

  2007cites this paper
• Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer

  2007cites this paper
• A Pilot Study of a Day One and Eight Every Three Weeks Administration of Docetaxel in Metastatic Cancer Patients

  2007cites this paper
• Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial.

  2007cites this paper
• Management of ovarian cancer. An impressive history of improvement in survival and quality of life.

  2006cites this paper
• Atypical presentations of carboplatin hypersensitivity reactions: characterization and management in patients with gynecologic malignancies.

  2006cites this paper
• Fallopian tube carcinoma: a review.

  2006cites this paper
• Management of Ovarian Cancer

  2006cites this paper
• Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer.

  2006cites this paper
• Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer.

  2006cites this paper
• Evaluation of combined nedaplatin and docetaxel therapy for human head and neck cancer in vivo.

  2006cites this paper
• Outcomes for patients with fallopian tube carcinoma managed with adjuvant chemotherapy following primary surgery: a retrospective university experience

  2006cites this paper
• Unresolved issues in the chemotherapeutic management of gynecologic malignancies.

  2006cites this paper
• Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.

  2005cites this paper
• Epithelial ovarian cancer: a review of current management.

  2005cites this paper
• Docetaxel in ovarian cancer

  2005cites this paper
• Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.

  2004cites this paper
• [Docetaxel and ovarian cancer].

  2004cites this paper
• Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

  2004cites this paper
• Docetaxel Versus Paclitaxel for Adjuvant Treatment of Ovarian Cancer: Case–Control Analysis of Toxicity

  2004cites this paper
• Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy.

  2004cites this paper
• Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.

  2004cites this paper
• Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

  2004cites this paper
• Chapter 31 – Primary Chemotherapy for Advanced Epithelial Ovarian Cancer

  2004cites this paper
• Carcinoma primario de trompa de Falopio. Presentación de 9 casos

  2004cites this paper
• Social support, anxiety and depression after chemotherapy for ovarian cancer: a prospective study.

  2004cites this paper
• A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours.

  2003cites this paper
• Docetaxel: an alternative taxane in ovarian cancer

  2003influential citation
• Chemotherapy for newly diagnosed and relapsed advanced ovarian cancer.

  2003cites this paper
• Managing taxane toxicities

  2003cites this paper
• Management of toxicities associated with the administration of taxanes

  2003cites this paper
• Management of advanced-stage primary carcinoma of the fallopian tube: case report and literature review.

  2003cites this paper
• The taxanes: toxicity and quality of life considerations in advanced ovarian cancer

  2003cites this paper
• Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma

  2003cites this paper
• Docetaxel: promising and novel combinations in ovarian cancer

  2003cites this paper
• Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: Active combination with low incidence of peripheral neuropathy

  2003cites this paper
• CARBOPLATIN COMBINED WITH DOCETAXEL AS A FIRST-LINE CHEMOTHERAPY IN EPITHELIAL OVARIAN CANCER

  2003cites this paper
• Docetaxel and carboplatin combination chemotherapy for recurrent endometrial cancer

  2003cites this paper
• DNA-binding agents.

  2003cites this paper
• Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel.

  2003cites this paper
• Natural product inhibitors of ovarian neoplasia.

  2003cites this paper
• Current management of fallopian tube carcinoma

  2002cites this paper
• Docetaxel in the treatment of ovarian cancer.

  2002cites this paper
• A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer

  2002cites this paper
• Contemporary Issues in the Safe Handling of Cytotoxic Agents

  2002cites this paper
• Ovarian cancer: progress and continuing controversies in management.

  2002cites this paper
• Standards, Options et Recommandations 2002 pour la prise en charge des patients atteints de carcinomes de site primitif inconnu (rapport abrégé)

  2002cites this paper
• DNA-binding agents.

  2002cites this paper
• Docetaxel in combination with carboplatin for chemo-naive patients with epithelial ovarian cancer

  2002cites this paper
• Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy.

  2002cites this paper
• Docetaxel in combination with carboplatin for chemo‐naive patients with epithelial ovarian cancer

  2002cites this paper
• Docetaxel in ovarian cancer: phase III perspectives and future development.

  2002cites this paper
• Ovarian cancer.

  2001cites this paper
• ASCO 2001: Critical Commentaries

  2001cites this paper
• KEY CONCEPTS Allergic and Pseudoallergic Drug Reactions

  year unknowncites this paper